Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-3-20
pubmed:abstractText
The tight regulation of protein kinase C (PKC) activity is crucial for maintaining normal cell proliferation. Excessive PKC activity leads to uncontrolled growth and malignant transformation. It has been reported that the activity of PKC is higher in astroglial cell lines than in normal astrocytes. Previously, we demonstrated that PKC epsilon is overexpressed in astroglial cell lines and in samples from primary high-grade astroglial brain tumors. Because there are no PKC epsilon isozyme-specific inhibitors, we chose a genetic approach to confirm that PKC epsilon is a potential target for inhibiting astroglial cell proliferation. We regulated the expression of a dominant negative PKC epsilon mutant (PKC epsilon 1-401 encoding amino acid 1-401) in U-373MG human astrocytoma cells using a tetracycline-regulated expression vector and established stable clones. Induction of expression of the dominant negative PKC epsilon mutant by the addition of doxycycline, a tetracycline derivative, completely blocked proliferation of U-373MG cells in proliferation and clonogenic assays. Although the induction of the dominant negative PKC epsilon mutant did not markedly affect mitogen-induced tyrosine phosphorylation of the mitogen-activated protein (MAP) kinases, it inhibited the induction of c-Fos protein expression by substance P (SP) and fetal bovine serum (FBS). These results clearly show that the expression of dominant negative PKC epsilon leads to the inhibition of U-373MG cellular proliferation demonstrating that this isozyme may be a potential therapeutic target for astroglial brain tumors.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1107-3756
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
373-80
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:11254876-Animals, pubmed-meshheading:11254876-Astrocytoma, pubmed-meshheading:11254876-Cattle, pubmed-meshheading:11254876-Cell Division, pubmed-meshheading:11254876-Enzyme Induction, pubmed-meshheading:11254876-Fetal Blood, pubmed-meshheading:11254876-Gene Expression Regulation, Enzymologic, pubmed-meshheading:11254876-Genes, Dominant, pubmed-meshheading:11254876-Growth Inhibitors, pubmed-meshheading:11254876-Humans, pubmed-meshheading:11254876-Isoenzymes, pubmed-meshheading:11254876-Mitogen-Activated Protein Kinases, pubmed-meshheading:11254876-Mutation, pubmed-meshheading:11254876-Phosphorylation, pubmed-meshheading:11254876-Protein Kinase C, pubmed-meshheading:11254876-Protein Kinase C-epsilon, pubmed-meshheading:11254876-Proto-Oncogene Proteins c-fos, pubmed-meshheading:11254876-Substance P, pubmed-meshheading:11254876-Tumor Cells, Cultured
pubmed:year
2001
pubmed:articleTitle
Regulated expression of a dominant negative protein kinase C epsilon mutant inhibits the proliferation of U-373MG human astrocytoma cells.
pubmed:affiliation
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't